FDA’s Regulatory Reforms to Unlock Competition and Lower Drug Costs
Abstract
This Viewpoint from the FDA explains efforts to remove burdensome criteria for biosimilar approvals and encourage use of biosimilars over branded biologics, which could lead to greater access to biosimilars for patients and reduce treatment costs.
Fields of Study & Subjects
Biosimilars and Bioanalytical Methods
Pharmaceutical Economics and Policy
Biomedical Ethics and Regulation
Publication details
- Journal / source
- JAMA
- Publisher
- American Medical Association (AMA)
- Volume
- 335
- Issue
- 17
- Pages
- 1473–1473
- Publication date
- 9 March 2026
- Language
- EN